IMCIVREE™(setmelanotide) Logo
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™(setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency
Format
JPEG
Source
Rhythm Pharmaceuticals, Inc.